CN106414457B - 具有多重模式抗疼痛活性的1-氧杂-4,9-二氮杂螺十一烷化合物的烷基衍生物 - Google Patents
具有多重模式抗疼痛活性的1-氧杂-4,9-二氮杂螺十一烷化合物的烷基衍生物 Download PDFInfo
- Publication number
- CN106414457B CN106414457B CN201580029239.4A CN201580029239A CN106414457B CN 106414457 B CN106414457 B CN 106414457B CN 201580029239 A CN201580029239 A CN 201580029239A CN 106414457 B CN106414457 B CN 106414457B
- Authority
- CN
- China
- Prior art keywords
- oxa
- ethyl
- unsubstituted
- diazaspiro
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14382209 | 2014-06-02 | ||
| EP14382209.6 | 2014-06-02 | ||
| PCT/EP2015/001115 WO2015185209A1 (en) | 2014-06-02 | 2015-06-02 | Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106414457A CN106414457A (zh) | 2017-02-15 |
| CN106414457B true CN106414457B (zh) | 2020-04-17 |
Family
ID=50972618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580029239.4A Expired - Fee Related CN106414457B (zh) | 2014-06-02 | 2015-06-02 | 具有多重模式抗疼痛活性的1-氧杂-4,9-二氮杂螺十一烷化合物的烷基衍生物 |
Country Status (21)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201615643A (zh) | 2014-06-02 | 2016-05-01 | 伊史帝夫博士實驗室股份有限公司 | 具有多重模式抗疼痛活性之１－氧雜－４，９－二氮雜螺十一烷化合物之烷基與芳基衍生物 |
| AR106444A1 (es) * | 2015-10-23 | 2018-01-17 | Esteve Labor Dr | Compuestos oxaazaespíricos con actividad contra el dolor |
| RS59956B1 (sr) | 2015-10-23 | 2020-03-31 | Esteve Pharmaceuticals Sa | Oksa-diazaspiro jedinjenja koja imaju aktivnost protiv bola |
| TN2018000122A1 (en) * | 2015-11-16 | 2019-10-04 | Esteve Labor Dr | Oxadiazaspiro compounds for the treatment of drug abuse and addiction |
| US10807970B2 (en) * | 2016-05-20 | 2020-10-20 | Esteve Pharmaceuticals, S.A. | Tetrahydropyran and thiopyran derivatives having multimodal activity against pain |
| FI3697795T3 (fi) * | 2017-10-17 | 2024-02-23 | Acondicionamiento Tarrasense | (R)-9-(2,5-difluorifenetyyli)-4-etyyli-2-metyyli-1-oksa-4,9-diatsaspiro[5.5]undekan-3-onin suoloja |
| WO2019158634A1 (en) | 2018-02-16 | 2019-08-22 | Esteve Pharmaceuticals, S.A. | Deuterated derivatives of 9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one |
| WO2019180188A1 (en) * | 2018-03-23 | 2019-09-26 | Esteve Pharmaceuticals, S.A. | Aminopropoxyphenyl and benzyl 1-oxa-4,9-diazaspiroundecane derivatives having multimodal activity against pain |
| WO2020157026A1 (en) * | 2019-01-28 | 2020-08-06 | Esteve Pharmaceuticals, S.A. | Hydroxylated derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain |
| WO2021018824A1 (en) | 2019-07-31 | 2021-02-04 | Esteve Pharmaceuticals, S.A. | Use of (r)-9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one for the treatment of nociceptive pain, neuropathic pain, osteoarthritis pain and cancer pain, while having reduced side effects compared to opioids |
| WO2024105225A1 (en) | 2022-11-18 | 2024-05-23 | Universitat De Barcelona | Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0061333A1 (en) * | 1981-03-23 | 1982-09-29 | Syntex (U.S.A.) Inc. | 9-(2-(3-Indolyl)ethyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones |
| US4353900A (en) * | 1981-10-19 | 1982-10-12 | Syntex (U.S.A.) Inc. | 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones |
| CN103517910A (zh) * | 2011-03-14 | 2014-01-15 | 沃泰克斯药物股份有限公司 | 作为离子通道调节剂的吗啉-螺环哌啶酰胺 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2133610B1 (cg-RX-API-DMAC7.html) * | 1971-04-15 | 1975-10-31 | Sumitomo Chemical Co | |
| US6114541A (en) | 1997-03-10 | 2000-09-05 | Hoffmann-La Roche Inc. | Method for the preparation of α-Bromo-Lactam derivatives |
| RU2477136C2 (ru) * | 2004-03-03 | 2013-03-10 | Вайтал Хэлф Сайнсис Пти Лтд | Алкалоидные составы |
| DE102005030051A1 (de) | 2005-06-27 | 2006-12-28 | Grünenthal GmbH | Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
| DE102005030061A1 (de) | 2005-06-27 | 2006-12-28 | Behr Gmbh & Co. Kg | Klimagerät |
| PT1961744E (pt) | 2005-11-18 | 2013-05-15 | Ono Pharmaceutical Co | Composto que contém um grupo básico e sua utilização |
| CN101622241B (zh) | 2007-03-01 | 2013-05-22 | 田边三菱制药株式会社 | 苯并咪唑化合物及其医药用途 |
| EP1982714A1 (en) | 2007-04-16 | 2008-10-22 | Laboratorios del Dr. Esteve S.A. | Pyrano-pyrazole-amines |
| EP2020414A1 (en) | 2007-06-20 | 2009-02-04 | Laboratorios del Dr. Esteve S.A. | spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis |
| EP2197876A1 (en) | 2007-08-29 | 2010-06-23 | Glaxosmithkline LLC | Thiazole and oxazole kinase inhibitors |
| CN102083839B (zh) | 2008-02-06 | 2014-03-26 | 阿斯利康(瑞典)有限公司 | 化合物 |
| GB201107985D0 (en) | 2011-05-13 | 2011-06-29 | Astrazeneca Ab | Process |
| US9751881B2 (en) | 2013-07-31 | 2017-09-05 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| TW201615643A (zh) | 2014-06-02 | 2016-05-01 | 伊史帝夫博士實驗室股份有限公司 | 具有多重模式抗疼痛活性之１－氧雜－４，９－二氮雜螺十一烷化合物之烷基與芳基衍生物 |
| TW201615642A (zh) | 2014-06-02 | 2016-05-01 | 伊史帝夫博士實驗室股份有限公司 | 具有多重模式抗疼痛活性的１－氧雜－４，９－二氮雜螺十一烷化合物之醯胺衍生物 |
-
2015
- 2015-06-01 TW TW104117583A patent/TWI685497B/zh not_active IP Right Cessation
- 2015-06-02 MX MX2016015760A patent/MX2016015760A/es unknown
- 2015-06-02 CN CN201580029239.4A patent/CN106414457B/zh not_active Expired - Fee Related
- 2015-06-02 TN TN2016000509A patent/TN2016000509A1/en unknown
- 2015-06-02 SG SG10201810660QA patent/SG10201810660QA/en unknown
- 2015-06-02 AU AU2015271248A patent/AU2015271248B2/en not_active Ceased
- 2015-06-02 SG SG11201609632UA patent/SG11201609632UA/en unknown
- 2015-06-02 NZ NZ726476A patent/NZ726476A/en not_active IP Right Cessation
- 2015-06-02 CA CA2949573A patent/CA2949573C/en active Active
- 2015-06-02 RU RU2016150518A patent/RU2720406C2/ru active
- 2015-06-02 JP JP2016570805A patent/JP6611736B2/ja not_active Expired - Fee Related
- 2015-06-02 BR BR112016027825-9A patent/BR112016027825B1/pt not_active IP Right Cessation
- 2015-06-02 WO PCT/EP2015/001115 patent/WO2015185209A1/en not_active Ceased
- 2015-06-02 MY MYPI2016704255A patent/MY177365A/en unknown
- 2015-06-02 UA UAA201613478A patent/UA124049C2/uk unknown
- 2015-06-02 KR KR1020167036612A patent/KR102468874B1/ko active Active
- 2015-06-02 AR ARP150101746A patent/AR100715A1/es active IP Right Grant
- 2015-06-02 EP EP15725236.2A patent/EP3149006B1/en active Active
- 2015-06-02 US US15/315,486 patent/US10246465B2/en active Active
-
2016
- 2016-11-16 IL IL249016A patent/IL249016B/en not_active IP Right Cessation
- 2016-11-18 PH PH12016502307A patent/PH12016502307B1/en unknown
- 2016-11-22 ZA ZA2016/08079A patent/ZA201608079B/en unknown
-
2019
- 2019-02-14 US US16/275,676 patent/US20190177337A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0061333A1 (en) * | 1981-03-23 | 1982-09-29 | Syntex (U.S.A.) Inc. | 9-(2-(3-Indolyl)ethyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones |
| US4353900A (en) * | 1981-10-19 | 1982-10-12 | Syntex (U.S.A.) Inc. | 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones |
| CN103517910A (zh) * | 2011-03-14 | 2014-01-15 | 沃泰克斯药物股份有限公司 | 作为离子通道调节剂的吗啉-螺环哌啶酰胺 |
Non-Patent Citations (1)
| Title |
|---|
| Antihypertensive 9-Substituted 1-Oxa-4,9-diazaspiro[5.5]undecan-3-ones;Robin D. Clark，等;《J. Med. Chem.》;19831231;第26卷(第6期);第855-861页 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102468874B1 (ko) | 통증에 대하여 다중모드 활성을 갖는 １-옥사-４,９-디아자스피로 운데칸 화합물의 알킬 유도체 | |
| JP6516773B2 (ja) | 疼痛に対する多様な活性を有する１−オキサ−４，９−ジアザスピロウンデカン化合物のアミド誘導体 | |
| JP6535687B2 (ja) | 疼痛に対する多様な活性を有する１−オキサ−４，９−ジアザスピロウンデカン化合物のアルキルおよびアリール誘導体 | |
| JP2017535545A (ja) | 疼痛に対する多様な活性を有するスピロ−イソキノリン−１，４’−ピペリジン化合物 | |
| CN105829297B (zh) | 具有抗疼痛的多重模式活性的哌啶化合物 | |
| US10022359B2 (en) | 1,9-diazaspiro undecane compounds having multimodal activity against pain | |
| CN108349999A (zh) | 用于治疗药物滥用和成瘾的氧杂二氮杂螺环化合物 | |
| WO2017198339A1 (en) | Tetrahydropyran and thiopyran derivatives having multimodal activity against pain | |
| US10508114B2 (en) | Spiro-isoquinoline-4,4′-piperidine compounds having multimodal activity against pain | |
| WO2020157026A1 (en) | Hydroxylated derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain | |
| JP2018521090A (ja) | 疼痛に対する多様な活性を有するアミド誘導体 | |
| HK1235773A1 (en) | Amide derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain | |
| HK1235773B (en) | Amide derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: Spain Barcelona Applicant after: Esteven Pharmaceutical Co.,Ltd. Address before: Spain Barcelona Applicant before: LABORATORIOS DEL DR. ESTEVE, S.A. |
|
| CB02 | Change of applicant information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230222 Address after: Barcelona, Spain Patentee after: Talasen Conditioning Co. Address before: Barcelona, Spain Patentee before: Esteven Pharmaceutical Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200417 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |